Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 4/20 | 0.43 |
| ▸ | DHFR | P00374 | 3/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4268061 | 0.78 | SRC (0.43) | SRCDHFRPIK3CGPABPC1ABL1 | |
| SCHEMBL4271416 | 0.77 | SRC (0.56) | SRCEGLN2CYP11B1CYP11B2ABL1 | |
| SCHEMBL13609525 | 0.74 | SRC (0.46) | SRCDHFRCYP11B1CYP11B2PIK3CG | |
| SCHEMBL20040430 | 0.71 | ALDH1A1 (0.45) | EGLN2CYP11B1CYP11B2 | |
| SCHEMBL18934331 | 0.68 | ALDH1A1 (0.54) | EGLN2CYP11B1CYP11B2 | |
| SCHEMBL4278783 | 0.68 | DHFR (0.52) | SRCDHFRPIK3CGPABPC1PDPK1 | |
| SCHEMBL3391242 | 0.68 | EGLN2 (0.43) | EGLN2CYP11B1CYP11B2ADORA2AHSP90AB1 | |
| SCHEMBL4265960 | 0.67 | DHFR (0.51) | SRCDHFRPIK3CGPABPC1PDPK1 | |
| SCHEMBL4264367 | 0.67 | DHFR (0.50) | SRCDHFRPIK3CGHSP90AB1PDGFRB | |
| SCHEMBL13609541 | 0.67 | DHFR (0.50) | SRCDHFRPIK3CGPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809614-B1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8481536-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2543376-A1 | Benzotriazine inhibitors of kinases | Targegen, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| CN-101426772-A | Benzotriazine inhibitors of kinases | TARGEGEN INC (US) | 2009-05-06 | — | — | CN | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1809614-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005096784-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | SRC, CAMK4, CAMK2G | SRC 1/4885DHFR 1676/4885EGLN2 2983/4885 |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | SRC, CAMK4, CAMK2G | SRC 1/4885DHFR 1676/4885EGLN2 2983/4885 |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | SRC, CAMK4, CAMK2G | SRC 1/4885DHFR 1676/4885EGLN2 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.